Pallas Capital Advisors LLC Acquires New Shares in Sotera Health (NASDAQ:SHC)

Pallas Capital Advisors LLC acquired a new stake in Sotera Health (NASDAQ:SHC) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 21,613 shares of the company’s stock, valued at approximately $334,000.

Other institutional investors and hedge funds have also modified their holdings of the company. CWM LLC lifted its stake in shares of Sotera Health by 86.1% in the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares during the last quarter. GAMMA Investing LLC lifted its position in Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after acquiring an additional 1,660 shares during the last quarter. Point72 DIFC Ltd lifted its position in Sotera Health by 556.6% during the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after acquiring an additional 5,544 shares during the last quarter. Acadian Asset Management LLC lifted its position in Sotera Health by 728.0% during the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after acquiring an additional 8,248 shares during the last quarter. Finally, Sandia Investment Management LP acquired a new position in Sotera Health during the 1st quarter worth $120,000. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analysts Set New Price Targets

SHC has been the subject of a number of research analyst reports. Barclays boosted their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.70.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the sale, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 55.12% of the stock is currently owned by insiders.

Sotera Health Stock Performance

NASDAQ:SHC opened at $15.67 on Friday. The firm’s 50-day moving average is $15.94 and its 200-day moving average is $13.53. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. The company has a market cap of $4.44 billion, a price-to-earnings ratio of 111.93 and a beta of 2.07.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.04. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The company had revenue of $277.00 million for the quarter, compared to the consensus estimate of $266.45 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Equities research analysts anticipate that Sotera Health will post 0.64 earnings per share for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.